Analyst Coverage| Firm | Analyst | | Bank of America Merrill Lynch | Gregg Gilbert | | Canaccord Genuity | Neil Maruoka | | Collins Stewart LLC | Louise Chen | | CRT Capital Group LLC | Tim Chiang | | Deutsche Bank | David Steinberg | | GMP Securities Ltd. | Cosme Ordonez | | Jefferies & Company, Inc. | Corey Davis, Ph.D. | | J.P. Morgan | Chris Schott | | Ladenburg Thalmann | Juan Sanchez | | Lazard Capital Markets | William Tanner | | Morgan Stanley | David Risinger | | Paradigm Capital | Alan Ridgeway | | Piper Jaffray & Co | David Amsellem | | RBC Capital Markets | Doug Miehm | | Stifel, Nicolaus & Company, Inc. | Annabel Samimy | | Susquehanna Financial Group | Gary Nachman | | TD Securities | Lennox Gibbs | | UBS Securities | Marc Goodman | | Wells Fargo Securities | Michael Tong, Ph.D. |
 |
| Valeant Pharmaceuticals International, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Valeant Pharmaceuticals International, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Valeant Pharmaceuticals International, Inc. or its management. Valeant Pharmaceuticals International, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
